Drugs / CT-1530
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02981745 | Apr 2017 → Sep 2018 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma, follicular lymphoma +1 | Centaurus Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-1530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02981745 ↗ |
| Action | Inhibit | “BTK inhibitor CT-1530” NCT02981745 ↗ |
| Target | BTK | “BTK inhibitor CT-1530” NCT02981745 ↗ |